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Abstract
Patients with polycythemia vera (PV) have a high incidence of thrombotic events (TEs), contributing to a greater mortality risk
than the general population. The relationship between hematocrit (HCT) levels and TE occurrence among patients with PV from
the Veterans Health Administration (VHA) was evaluated to replicate findings of the CYTO-PV trial with a real-world patient
population. This retrospective study used VHA medical record and claims data from the first claim with a PV diagnosis (index)
until death, disenrollment, or end of study, collected between October 1, 2005, and September 30, 2012. Patients were aged
≥ 18 years at index, had ≥ 2 claims for PV (ICD-9-CM code, 238.4) ≥ 30 days apart during the identification period, continuous
health plan enrollment from 12 months pre-index until end of study, and ≥ 3 HCTmeasurements per year during follow-up. This
analysis focused on patients with no pre-index TE, and with all HCT values either < 45% or ≥ 45% during the follow-up period.
The difference in TE risk between HCT groups was assessed using unadjusted Cox regression models based on time to first TE.
Patients (N = 213) were mean (SD) age 68.9 (11.5) years, 98.6% male, and 61.5% white. TE rates for patients with HCT values
< 45% versus ≥ 45% were 40.3% and 54.2%, respectively. Among patients with ≥ 1 HCT before TE, TE risk hazard ratio was
1.61 (95% CI, 1.03–2.51; P = 0.036). This analysis of the VHA population further supports effective monitoring and control of
HCT levels < 45% to reduce TE risk in patients with PV.
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Introduction
Patients with polycythemia vera (PV) are at risk for arterial
and venous thrombotic events (TEs). In a large international,
retrospective study, 12% of patients with PV had an arterial
TE and 9% had a venous TE over a median follow-up of
7 years [1]. Across several studies, rates of arterial and venous
TEs in patients with PV ranged from 0.7 to 2.1 and 0.5 to 2.0
per 100 person-years, respectively [2–5]. Thrombotic compli-
cations have been reported as a leading cause of death for
patients with PV, and prior thrombosis, particularly venous,
has been identified as prognostic for overall survival [1].
Taken together, TEs may contribute to the lower survival rate
observed in patients with PV compared with the general pop-
ulation [6].
The National Comprehensive Care Network Clinical
Practice Guidelines in Oncology (NCCN Guidelines®) em-
phasizes prevention of thrombosis occurrence and recurrence
as a primary treatment goal for PV, along with controlling
disease-related symptoms [7]. This recommendation is sup-
ported by the findings of the European Collaboration on
Low-Dose Aspirin in Polycythemia Vera (ECLAP) study,
which observed a significant reduction in the risk of TE and
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death from cardiovascular causes in patients treated with as-
pirin [8]. In addition, hematocrit (HCT) control is associated
with reduced thrombotic risk in patients with PV, as observed
in the Italian Cytoreductive Therapy in Polycythemia Vera
(CYTO-PV) trial [9]. In brief, the CYTO-PV trial randomized
participants 1:1 to 2 groups: one with an HCT target of < 45%
(low-HCT group) and the other with an HCT target of 45 to
50% (high-HCT group). Patients in the low-HCT group had a
significantly lower rate of cardiovascular death and major
thrombosis than those in the high-HCT group [9].
The study described here reports the results of a retrospec-
tive analysis of Veterans Health Administration (VHA) claims
data. The VHA is the largest integrated healthcare system in
the USA and provides real-world data on a robust patient
population. The aim of this study was to investigate the rela-
tionship between HCT levels and TE occurrence among pa-
tients with PVand is the first to replicate the CYTO-PV find-
ings in a real-world setting.
Methods
Database characteristics
The VHA consists of 150 medical centers and nearly 1400
community-based outpatient clinics, veteran’s centers, and do-
miciliary. In 2014, 9.11 million patients were enrolled in the
VHAhealthcare system; enrollees were primarily non-Hispanic
white (82.3%) men (91.0%) under 65 years old (54.8%) [10].
VHA records provide longitudinal data, capturing the full epi-
sode of care of the VHA population. The dataset analyzed here
included de-identified patient-level data from 21 Veterans
Integrated Service Networks linking inpatient, outpatient, phar-
macy, laboratory, enrollment, and vital sign databases.
Study design
This retrospective observational claims study analyzed VHA
Medical SAS® Dataset data cataloged between October 1,
2005, and September 30, 2012 (Fig. 1). Patients were moni-
tored from the index date (defined as the date of each patient’s
first claim with a PV diagnosis during the identification period
[October 1, 2006, to September 30, 2007]) until death,
disenrollment, or end of the follow-up period (September
30, 2012; Fig. 1).
Patients
Patients included in the analysis had ≥ 2 claims for PV
(International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] code: 238.4) ≥ 30 days
apart during the identification period, were ≥ 18 years old on
the index date, were continuously enrolled in a health plan
with medical and pharmacy benefits from 12 months pre-
index until the end of the study period, and had ≥ 3 HCT
and ≥ 3 white blood cell (WBC) measurements per year dur-
ing the follow-up period (WBC data analyzed and reported in
a separate study). Patients with a pre-index TE were excluded
from the primary analysis. This analysis included patients
whose observed HCT levels were consistently within strict
boundaries, always either < 45% or ≥ 45% during the
follow-up period.
Definition of TE
Patients who had a TE were defined as those with a diagnosis
in medical claims during the follow-up period for at least one
of the following conditions: ischemic stroke, acute myocardial
infarction, deep vein thrombosis, pulmonary embolism, tran-
sient ischemic attack, peripheral arterial thrombosis, and su-
perficial thrombophlebitis. More than one type of TE could be
recorded in a single visit; therefore, the first event could in-
clude more than one type of TE per patient.
Statistical analyses
Patient demographics and disease characteristics, baseline co-
morbidities, and TEs were described using descriptive statis-
tics. Comorbid conditions were measured using the Deyo-
Charlson Comorbidity Index, which assigns a weighted score
ranging from 1 to 6 according to disease severity for 19 con-
ditions [11], and the Chronic Disease Score, an aggregate
comorbidity measure based on medication use (derived from
pharmacy claims data) [12]. Any differences between the two
HCT groups in the risk of TE were assessed using unadjusted
Cox regression models based on time to first TE. For patients
with a TE during follow-up, only those with ≥ 1 HCT mea-
surement before the event were included in the Cox regression
models. Time to first TE was defined as the period between
index date and first claim associated with a TE diagnosis;
patients were censored at the time of death, disenrollment, or
end of the follow-up period. The primary analysis included
patients without a history of TE before the index date; a sen-
sitivity analysis including patients with a history of TE prior to
the index period was also performed.
Results
Patients
There were 3943 patients who had ≥ 2 medical claims for PV
during the identification period. In total, 1876 had ≥ 3 HCT
and ≥ 3 WBC measurements per year, of whom 342 had con-
sistent HCT status throughout follow-up. Of these patients,
213 did not experience a TE during the pre-index period
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(HCT < 45%, n = 154; HCT ≥ 45%, n = 59; Fig. 2) and were
included in the primary analysis.
Among the 213 patients included in the analysis, most were
male (98.6%) and white (61.5%), with a mean (SD) age of
68.9 (11.5) years (Table 1). The mean (SD) Deyo-modified
Charlson Comorbidity Index score and Chronic Disease Score
were 1.46 (1.56) and 7.34 (4.37), respectively, indicating a
notable pre-index comorbidity burden. The most common co-
morbidities were hypertension (72.8%), dyslipidemia
(37.6%), chronic obstructive pulmonary disease (24.9%),
and diabetes (17.4%). Use of smoking cessation therapy (used
as a surrogate measure of smoking rate) was present for 23.9%
of the patients.
TEs during follow-up
Among qualifying patients, 44.1% (94/213) experienced a TE
during follow-up (mean follow-up, 2.3 years; rate per 100 per-
son-years, 18.9; Fig. 3). The 3 most common types of TE re-
corded as the first event during follow-up were ischemic stroke
(21.6%, 46/213), deep vein thrombosis (12.2%, 26/213), and
transient ischemic attack (9.4%, 20/213; Table 2). Patients with
HCT levels < 45% (n = 154; median follow-up, 2.48 years)
compared with those with levels ≥ 45% (n = 59; median fol-
low-up, 1.97 years) had a lower risk of TE (40.3% vs 54.2%,
respectively; Fig. 3). A statistically significant increased risk of
TE was observed among patients with HCT levels ≥ 45% com-
pared with those with HCT levels < 45% (hazard ratio [HR]
calculation including 208 patients with ≥ 1 HCT value before
first TE, 1.61; 95% CI, 1.03–2.51; P = 0.036).
Mean body mass index (BMI) at the index date was lower
among patients with a consistent HCT < 45% who did not
experience a TE compared with those who did experience a
TE (26.2 vs 29.4 kg/m2, respectively). Patients with a consis-
tent HCT ≥ 45% had nearly identical mean index date BMI,
regardless of TE during follow-up (31.2 vs 31.3 kg/m2).
The sensitivity analysis conducted including patients with
and without TE prior to index (n = 342) had similar results to
the primary analysis (55.6% vs 76.9% between the < 45% and
≥ 45% groups, respectively; HR calculation including 322 pa-
tients with ≥ 1 HCT value before first TE, 1.95; 95%CI, 1.46–
2.61; P < 0.0001).
Discussion
This retrospective analysis of VHA claims data evaluated the
relationship between HCT levels and TE occurrence among
patients with PV in a real-world setting. Results from this
analysis are consistent with those reported in CYTO-PV [9],
which identified increased risk of TE in patients with HCT
≥ 45% versus < 45% and a risk of death from cardiovascular
causes or major thrombosis that was 4 times greater in the
group with high HCT. In the present study, patients with
HCT levels that were consistently ≥ 45% had a 70% increased
risk of TE compared with those with HCT levels that were
consistently < 45%.
Patients with consistently high HCT (≥ 45%) have subop-
timal control of disease and may require changes to the man-
agement of their disease, such as initiation of effective
cytoreductive therapy, to improve clinical outcomes. A sepa-
rate analysis of cytoreductive treatment patterns in predomi-
nantly (73.8%) high-risk patients with PV from the VHA pa-
tient population revealed that only 23.2% of patients had a
record of any pharmacologic cytoreductive treatment [13], in
contrast to NCCN Guidelines® [7]. Among patients with
HCT levels < 45%, effective monitoring and maintenance
may lead to a reduction in the risk of TE by identifying chang-
es in HCT control and cardiovascular risk factors before the
occurrence of a TE. The association between the occurrence
of TE and the effectiveness of treatments used to maintain
Fig. 1 Study design schematic. * ≥ 12 months. †Patients were monitored from index date until the date of the earliest event: death, disenrollment, or end
of the study period
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HCT values below a 45% threshold was outside the scope of
this study and not assessed.
When interpreting the results of the current study, it is im-
portant to note that the VHA patient population is a unique
population with key differences from the general patient pop-
ulation. The VHA patient population analyzed in this study
was predominantly male (98.6%). Overall, rates of cardiovas-
cular risk factors and comorbidities are higher in the VHA
patient population versus the general population [14].
Baseline comorbidity scores indicated a significant comorbid
disease burden, even compared with patients with PV in the
general US population (Charlson Comorbidity Index score,
1.29 vs 0.8) [5]. Furthermore, several of the most common
baseline comorbid conditions (i.e., hypertension, dyslipid-
emia, smoking [based on use of smoking cessation therapy],
and diabetes) are among the risk factors typically associated
with cardiovascular disease [15]. Although not recorded in
this study, psychological comorbidities (e.g., posttraumatic
stress disorder) [16] and psychosocial issues (e.g., homeless-
ness) [17] have also been documented in the VHA patient
Fig. 2 Patient selection and attrition. HCT, hematocrit; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; PV,
polycythemia vera; TE, thrombotic event; WBC, white blood cell
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population and could pose challenges in properly managing
TEs. Taken together, these attributes of the VHA patient pop-
ulation may have contributed to the high TE rate observed in
this analysis, with more than a quarter of those with no pre-
index TE experiencing a TE during follow-up (rate of 18.9 per
100 person-years). In comparison, a recent observational
Table 1 Patient demographics
and clinical characteristics at
index date
Characteristic No pre-index TE and consistent HCT
Total
(n = 213)
HCT < 45% (n = 154) HCT ≥ 45% (n = 59)
Mean (SD) age, years 68.9 (11.5) 71.8 (10.7) 61.2 (10.0)
Male, n (%) 210 (98.6) 151 (98.1) 59 (100)
Race/ethnicity, n (%)
White 131 (61.5) 97 (63.0) 34 (57.6)
Black 19 (8.9) 13 (8.4) 6 (10.2)
Hispanic 10 (4.7) 8 (5.2) 2 (3.4)
Other 53 (24.9) 36 (23.4) 17 (28.8)
Mean (SD) BMI, kg/m2 28.5 (12.3) 27.5 (13.6) 31.3 (6.9)
Comorbidities
Mean (SD) Deyo-modified CCI score 1.46 (1.56) 1.64 (1.66) 0.97 (1.13)
Mean (SD) CDS 7.34 (4.37) 7.65 (4.43) 6.53 (4.10)
Common comorbidities and
health-related behaviors, n (%)
Hypertension 155 (72.8) 115 (74.7) 40 (67.8)
Dyslipidemia 80 (37.6) 52 (33.8) 28 (47.5)
COPD 53 (24.9) 35 (22.7) 18 (30.5)
Diabetes 37 (17.4) 29 (18.8) 8 (13.6)
Cardiovascular event 33 (15.5) 24 (15.6) 9 (15.3)
Bleeding 23 (10.8) 18 (11.7) 5 (8.5)
Asthma 6 (2.8) 5 (3.2) 1 (1.7)
Smokinga 51 (23.9) 28 (18.2) 23 (39.0)
BMI, body mass index; CCI, Charlson Comorbidity Index; CDS, Chronic Disease Score; COPD, chronic ob-
structive pulmonary disease; HCT, hematocrit; TE, thrombotic event
a Based on use of smoking cessation therapy in claims
Fig. 3 TE during follow-up. HCT, hematocrit; HR, hazard ratio; TE, thrombotic event. *HR calculation based on patients with ≥ 1 HCT value before first
TE (n = 208). †HR calculation based on patients with ≥ 1 HCT value before first TE (n = 322)
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study of patients with PV in the general US population (N =
8124) reported a rate of 1.43 per 100 person-years [5].
Body mass index is also an important contributor to
adverse cardiovascular outcomes and risk [18]. Among pa-
tients with low HCT (< 45%), those who experienced a TE
during follow-up had higher index BMI. BMI may be more
indicative of TE risk than comorbidities, as scores for both
Charlson Comorbidity Index and Chronic Disease Score
were higher for the low-HCT (< 45%) group than the
high-HCT (≥ 45%) group.
A key strength of this analysis is that the methodology
used real-world data from patients in 2 groups based on con-
sistent HCT levels < 45% or ≥ 45%, similar to the groups
evaluated in the CYTO-PV study. Limitations of this study
are attributable to its retrospective design and the accuracy of
the VHA medical database. The sample sizes for the consis-
tent HCT cohorts were small; however, they were similar to
the population sizes recorded in the CYTO-PV study (< 45%,
n = 182; ≥ 45%, n = 183) [9]. The real-world nature of the
study data means that the characteristics of the two cohorts
may differ, and could not be controlled for without making
the model unstable. The outcome variables (e.g., TE) and
other clinical conditions (e.g., PV) were identified using
ICD-9-CM codes, which are subject to potential miscoding.
This was also applicable to smoking rates, which were likely
underestimated, as they were identified using ICD-9-CM
codes for management associated with smoking cessation.
Moreover, potential misclassification of HCT values could
have led to information bias. Platelet counts as well as over-
the-counter aspirin use were not available in the VHA data-
base. Lastly, it is important to note that because of the large
difference in sociodemographic characteristics, health status,
resource use, and costs between the VHA population and the
general US population, the results of this study may not be
generalizable to the US population.
Conclusion
Among VHA patients with PV, those with HCT levels
consistently ≥ 45% had a significantly higher risk of TE
than patients with HCT levels consistently < 45%. The
results of this retrospective analysis of a real-world popu-
lation are in agreement with findings from the CYTO-PV
study and further support effective monitoring and man-
agement of HCT levels < 45% to reduce the risk of TE in
patients with PV.
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Table 2 Rates and types of TE during follow-up
No pre-index TE and consistent HCT
Total (n = 213) HCT < 45% (n = 154) HCT ≥ 45% (n = 59)
Patients, n (%) Incidence rate
per 100 person-years
Patients, n (%) Incidence rate
per 100 person-years
Patients, n (%) Incidence rate
per 100 person-years
TE 94 (44.1) 18.9 62 (40.3) 16.2 32 (54.2) 27.5
Ischemic stroke 46 (21.6) 9.2 29 (18.8) 7.6 17 (28.8) 14.6
Deep vein thrombosis 26 (12.2) 5.2 21 (13.6) 5.5 5 (8.5) 4.3
Transient ischemic attack 20 (9.4) 4.0 10 (6.5) 2.6 10 (17.0) 8.6
Acute myocardial infarction 15 (7.0) 3.0 12 (7.8) 3.1 3 (5.1) 2.6
Pulmonary embolism 15 (7.0) 3.0 11 (7.1) 2.9 4 (6.8) 3.4
Peripheral arterial thrombosis 5 (2.4) 1.0 1 (0.7) 0.3 4 (6.8) 3.4
Superficial thrombophlebitis 3 (1.4) 0.6 2 (1.3) 0.5 1 (1.7) 0.9
HCT, hematocrit; TE, thrombotic event
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